SERA: the cashflow

MyFinsight

For the quarter ending 2025-09-30, SERA had -$935K decrease in cash & cash equivalents over the period. -$6,589K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Revenues	16	-
Cost of revenue	41	-
Payroll related expenses	4,360	-
Consulting and professional fees	1,514	-
Stock-based compensation expense	1,254	-
Equipment lab supplies and facility expenses	422	-
Clinical studies and outside processing	394	-
Depreciation and amortization	214	-
Other segment items	797	-
Loss from operations	-8,980	-
Interest expense	2	-
Other income, net	1,168	-
Net loss	-7,814	-16,233
Depreciation and amortization	243	453
Stock-based compensation	1,254	2,837
Non-cash lease expense	125	301
Non-cash investment income, net	-33	-39
Other	0	5
Accounts receivable	-3	-17
Other receivables	0	-19
Prepaid expenses and other assets	488	-603
Accounts payable	52	-967
Accrued and other current liabilities	16	-87
Deferred revenue	99	-3
Net cash used in operating activities	-6,477	-13,026
Purchases of marketable securities	7,969	71,863
Proceeds from maturities and sales of marketable securities	13,250	32,586
Purchases of property and equipment	112	284
Purchase of intangible assets	0	0
Net cash (used in) provided by investing activities	5,169	-39,561
Proceeds from public offering of common stock, net of issuance costs	0	53,610
Proceeds from exercise of stock options	393	48
Proceeds from employee stock purchase plan	0	75
Finance lease principal payments	20	173
Net cash provided by financing activities	373	53,560
Net increase (decrease) in cash and cash equivalents	-935	973
Cash and cash equivalents at beginning of period	4,043	-
Cash and cash equivalents at end of period	4,081	-

Unit: Thousand (K) dollars